指南与共识淋巴瘤

灰区淋巴瘤的临床病理共识研究:具有介于弥漫大B细胞淋巴瘤与经典型霍奇金淋巴瘤之间特征的病变

Clinicopathologic consensus study of gray zone lymphoma with features intermediate between DLBCL and classical HL.
指南 / 共识 · Blood Adv · 2017-12-11

该共识研究对北美15个学术中心诊断的68例灰区淋巴瘤(GZL)进行中心病理复核,仅26例(38%)确认为GZL。确认与重新分类病例的纵隔受累比例(69% vs 41%,P=0.038)及>1处结外病灶比例(0% vs 25%,P=0.019)存在差异;低白蛋白血症为不良预后因素,一线CHOP±R与改善3年PFS相关。

要点

  • 中心病理复核后仅38%(26/68)的GZL诊断被确认,42例被重新分类为其他淋巴瘤。
  • 确认GZL较重新分类病例更常见纵隔受累(69% vs 41%),更少>1处结外病灶(0% vs 25%)。
  • 低白蛋白血症与较差3年PFS相关(12% vs 64%),一线CHOP±R与较好3年PFS相关(70% vs 20%)。

核心结论

  • GZL的准确诊断仍具挑战性,需要改进治疗策略。
  • 中心病理复核对GZL诊断共识至关重要。
  • 低白蛋白血症为GZL不良预后因素,一线CHOP±R与改善PFS相关。

研究设计与样本

  • 多中心共识研究,纳入北美15个学术中心诊断的68例GZL病例,经中心病理复核达成共识。
  • 中位随访44个月。

主要发现

  • 68例中仅26例(38%)经中心复核确认为GZL,42例被重新分类:结节硬化型经典型霍奇金淋巴瘤27例(含10例结节硬化2级)、淋巴细胞为主型霍奇金淋巴瘤4例、弥漫大B细胞淋巴瘤4例、EBV阳性弥漫大B细胞淋巴瘤3例、原发纵隔大B细胞淋巴瘤2例、富于淋巴细胞经典型霍奇金淋巴瘤及B细胞淋巴瘤非特指型各1例。
  • GZL确认病例免疫组化:CD20+ 83%、PAX5+ 100%、BCL6+ 20%、MUM1+ 100%、CD30+ 92%、EBV+ 4%。
  • 确认GZL vs 重新分类病例:纵隔受累69% vs 41%(P=0.038),>1处结外病灶0% vs 25%(P=0.019)。
  • 确认GZL vs 重新分类病例:3年PFS 39% vs 58%(P=0.19),3年OS 95% vs 85%(P=0.15)。
  • 结节硬化2级重新分类患者PFS与确认GZL相似。

关键数值与推荐

  • GZL共识诊断中形态学关键(如肿瘤细胞丰富程度)。
  • 免疫组化显示普遍B细胞来源、常见CD30表达、EBV罕见阳性。
  • 低白蛋白血症为不良预后因素(3年PFS 12% vs 64%,P=0.01)。
  • 一线CHOP±R与改善3年PFS相关(70% vs 20%,P=0.03)。

临床怎么用

  • GZL诊断应经中心病理复核以达成共识。
  • 低白蛋白血症可用于GZL预后评估。
  • 一线CHOP±R可能与改善PFS相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Gray zone lymphoma (GZL) is described as sharing features with classical Hodgkin lymphoma (cHL) and diffuse large B-cell lymphoma (DLBCL). However, there remains complexity in establishing diagnosis, delineating prognosis, and determining optimum therapy. Sixty-eight cases diagnosed as GZL across 15 North American academic centers were evaluated by central pathology review to achieve consensus. Of these, only 26 (38%) were confirmed as GZL. Morphology was critical to GZL consensus diagnosis (eg, tumor cell richness); immunohistochemistry showed universal B-cell derivation, frequent CD30 expression, and rare Epstein-Barr virus (EBV) positivity (CD20+, 83%; PAX5+, 100%; BCL6+, 20%; MUM1+, 100%; CD30+, 92%; EBV+, 4%). Forty-two cases were reclassified: nodular sclerosis (NS) cHL, n = 27 (including n = 10 NS grade 2); lymphocyte predominant HL, n = 4; DLBCL, n = 4; EBV+ DLBCL, n = 3; primary mediastinal large BCL n = 2; lymphocyte-rich cHL and BCL-not otherwise specified, n = 1 each. GZL consensus-confirmed vs reclassified cases, respectively, more often had mediastinal disease (69% vs 41%; P = .038) and less likely more than 1 extranodal site (0% vs 25%; P = .019). With a 44-month median follow-up, 3-year progression-free survival (PFS) and overall survival for patients with confirmed GZL were 39% and 95%, respectively, vs 58% and 85%, respectively, for reclassified cases (P = .19 and P = .15, respectively). Interestingly, NS grade 2 reclassified patients had similar PFS as GZL consensus-confirmed cases. For prognostication of GZL cases, hypoalbuminemia was a negative factor (3-year PFS, 12% vs 64%; P = .01), whereas frontline cyclophosphamide, doxorubicin, vincristine, and prednisone ± rituximab (CHOP±R) was associated with improved 3-year PFS (70% vs 20%; P = .03); both factors remained significant on multivariate analysis. Altogether, accurate diagnosis of GZL remains challenging, and improved therapeutic strategies are needed.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Pilichowska M, Pittaluga S, Ferry JA, et al. Clinicopathologic consensus study of gray zone lymphoma with features intermediate between DLBCL and classical HL. Blood Adv. 2017. PMID: 29296913. doi:10.1182/bloodadvances.2017009472

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。